GLP-1–GIP–lanifibranor quintuple agonist outperforms existing drugs in obese mice
Updated
Updated · Nature.com · Apr 29
GLP-1–GIP–lanifibranor quintuple agonist outperforms existing drugs in obese mice
5 articles · Updated · Nature.com · Apr 29
In preclinical studies, GLP-1–GIP–lanifibranor reduced body weight, food intake, and blood glucose more effectively than semaglutide or GLP-1R–GIPR co-agonists in obese and insulin-resistant mice.
The new drug also improved insulin sensitivity, liver health, and cardiovascular function, while avoiding adverse effects like fluid retention or renal impairment seen with some PPAR agonists.
GLP-1–GIP–lanifibranor’s targeted delivery enables much lower dosing than standalone lanifibranor, suggesting substantial therapeutic potential for obesity and type 2 diabetes, though further studies are needed to confirm efficacy in humans.
After success in mice, what is the realistic timeline for this obesity 'super-drug' to reach patients?
Can this new drug escape the side effects that plagued one of its core components in past trials?
In a market of giants, can a preclinical drug challenge the next generation of obesity treatments?
Will this highly complex 'five-in-one' drug be affordable enough to truly impact the obesity epidemic?
What are the unknown long-term risks of targeting five metabolic pathways with a single molecule?
Is combining five mechanisms in one molecule the future, or a path to unmanageable complexity?